• Investment Director at Jianxin Capital

Paul D. Rennert, PhD

• Immuno-oncology at Aleta, Biogen, and X-Rx

Andrew X. Zhu, PhD

Simon Fricker, PhD

• Chemistry at Vertex Pharmaceuticals

Lixin Yang

Team

John Tagliamonte, MBA

• Cancer biology at AnorMed and Genzyme

Jin (Jim) Wang

• 20+ years of experience in business development

• ​Formerly at Johnson and Johnson, ImmunoGen, Anchor, and Oxyrane
  

CO-FOUNDER, CBO (PART-TIME)

• 20+ years of experience in founding, investing, and managing innovative therapeutic R&D companies

Advisors

Robert Perni, PhD

Founder 

Yanjun Ma

• Professor of Harvard Medical School

• Oncologist in Massachusetts General Hospital 

Eric Cheng, MD, MBA

Management

• 30 years experiences in pharmaceuticals industry

• President of Venture Leader Group

• Former President of TEEC Angel Fund 

• Executive Vice President of Technology and Research, Microsoft

WntRx's team is comprised of world-leading cancer researchers and biotech industry innovators whose work lies at the forefront of cancer therapeutics development. Management is guided by distinguished advisors, including industry leaders and highly experienced investors and entrepreneurs.

• 15+ years of experience in founding, investing, and managing innovative therapeutic R&D companies

CSO 

EXECUTIVE CHAIRMAN

David Zhu, PhD

Yeung Heung Yeung, PhD

CORPORATE DEVELOPMENT, COO